Bipolar Disorders Treatment Market Research Report: Information by Drug Type (Mood Stabilizer, Anticonvulsant, Antipsychotic Drug, and Antidepressant Drug), Mechanism of Action (Selective Serotonin Reuptake Inhibitor, Serotonin Norepinephrine Reuptake Inhibitor, Monoamine Oxidase Inhibitors, Beta Blockers, and Tricyclic Antidepressant Drug), End User (Hospitals and Clinics, Multispecialty Centers, and Others), and Region (the Americas, Europe, Asia-Pacific, and the Middle East & Africa)—Forecast till 2030
ID: MRFR/Pharma/1037-HCR | 85 Pages | Published By Kinjoll Dey on March 2023
Speak to Analyst
Request a Free Sample
Bipolar Disorders Treatment Market
The bipolar disorders treatment market is anticipated to reach USD 5604.83 Million by 2030 at 3.40% CAGR during the forecast period 2022-2030
$5604.83 Million
3.40%%
North America
2022-2030
Bipolar Disorders Treatment Market Scenario
The bipolar disorders treatment market is anticipated to reach USD 5604.83 Million by 2030 at 3.40% CAGR during the forecast period 2022-2030 Bipolar disorder is a manic-depressive disorder, which is a type of mental illness. It is characterized by mood swings and mood episodes appear during the illness. Manic and depressive episodes are common mood episodes observed in bipolar disorders. The government initiatives for treatment of bipolar disorders, advancement in combination drugs, and growing demand for antidepressant drugs are expected to drive the growth of the market. Moreover, growing research and development activities conducted by government and nonprofit organizations are contributing to the growth of the market. For instance, Harvard University started Harvard brain science initiative (HBI) for R&D on bipolar disorders. This program has provided USD 3 million in funds to the research and development related to bipolar disorders. The side effects associated with therapy, low diagnosis rate, and dearth of experts may hamper the growth of the global market during the assessment period.  SegmentationThe global bipolar disorders and treatment market has been segmented on the basis of drug class, mechanism of action, and end user. Based on drug type, the global market has been classified into mood stabilizer, antipsychotic drugs, antianxiety drugs, antidepressant drugs, anticonvulsants, and others. Based on the mechanism of action, the global market has been segmented into selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, monoamine oxidase inhibitors, beta-blockers, tricyclic antidepressant drug, and others. The global market, by end user, has been segmented into hospitals and clinics, multispecialty centers, and others. The bipolar disorders treatment market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European market has been bifurcated into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bipolar disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.  Key PlayersAllergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary) are some of the key players operating in the bipolar disorders treatment market.  Â
Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas are likely to dominate the global bipolar disorders and treatment market owing to technological advancement, presence of major players in the region, well-established healthcare system, and increasing cases of bipolar disorders in the region. According to the National Institute of Mental Health (NIMH), approximately 3% of adults in the US were suffering from bipolar disorders in 2016 and this percentage is expected to increase significantly in the future due to changing lifestyles. Â The European market is expected to be the second-largest bipolar disorders and treatment market. The market growth in this region can be attributed to the increasing number of mental disorders, increasing government funding for treatment of bipolar disorders, and growing research and development activities related to mental health. For instance, in November 2017, Mental Health UK launched a partnership with Lloyds Banking Group to help bipolar disorder patients and to manage and improve their financial and mental health. Asia-Pacific is expected to be the fastest-growing bipolar disorders and treatment market during the forecast period owing to the increasing prevalence of genetic disorders, growing awareness about bipolar disorders, and rising investment by major players in the region. According to the Black Dog Institute, bipolar disorder is related with the genetic condition of an individual, if the parents are suffering from bipolar disorder it is more than 10% likely that their children will experience the same condition in future. The Middle East & Africa is expected to account for the smallest share of the bipolar disorders treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.Bipolar disorders treatment market, by Drug Type
- Mood Stabilizer
- Antipsychotic Drugs
- Antianxiety Drugs
- Antidepressant drugs
- Anticonvulsants
- Others
Bipolar disorders treatment market, by Mechanism of Action
- Selective Serotonin Reuptake Inhibitor
- Serotonin Norepinephrine Reuptake Inhibitor
- Monoamine Oxidase Inhibitors
- Beta-Blockers
- Tricyclic Antidepressant Drug
- Others
Bipolar disorders treatment market, by End User
- Hospitals and Clinics
- Multispecialty Centres
- Others
Bipolar disorders treatment market, by Region
- Americas
- North America
- US
- Canada
- Latin America
- Europe
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- Middle East
- Africa
Bipolar disorders treatment market, by Key Players
- Allergan
- AstraZeneca
- Eli Lilly and Company
- GlaxoSmithKline
- Abbott
- Bristol-Myers Squibb
- Johnson & Johnson
- Pfizer Inc.
- Cephalon Inc.
- Otsuka America Pharmaceutical Inc.
- Gedeon Richter plc
- Others
Intended Audience
- Bipolar disorders and treatment centers
- Contract research organizations (CROs)
- Research and development (R&D) companies
- Government research laboratories
- Independent research laboratories
- Government and independent regulatory authorities
- Market research and consulting service providers
- Medical research laboratories
- Academic medical institutes and universities
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2030 :USD 5604.83 Million |
| CAGR | 3.40% (2022–2030) |
| Base Year | 2021 |
| Forecast Period | 2022-2030 |
| Historical Data | 2020 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Drug Type, Mechanism of Action and End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Allergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary) |
| Key Market Opportunities | side effects associated with therapy, low diagnosis rate, and dearth of experts |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
bipolar disorders treatment market was valued at USD 5.6 billion in 2018.
global market is expected to exhibit a strong 3.40% CAGR over the forecast period.
The growing prevalence of bipolar disorders is the major driver for the market.
The Americas and Europe dominate the global bipolar disorder treatment market.
Leading players in the market include Allergan, AstraZeneca, and Pfizer, among others.
